Top Markets
Coin of the day
Ambrx Biopharma Inc. Ambrx Biopharma Inc.

Ambrx Biopharma Inc.

AMAM
Rangering i aksjer #6980
Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused... Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is currently undergoing evaluation in several clinical investigations. These include pivotal Phase 2/3 trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer, alongside studies for other solid tumors. Additionally, Ambrx is progressing two earlier-stage drug candidates: ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for prostate cancer and other solid tumor indications; and ARX305, an anti-CD70 ADC, currently in investigational new drug (IND)-enabling studies for potential applications in renal cell carcinoma and other cancers. The company's portfolio also encompasses multiple immuno-oncology programs. Among these are ARX822, a fab-small molecule bispecific therapeutic in preclinical development for various cancers, and ARX102, an immuno-oncology IL-2 pathway agonist intended to stimulate the patient's immune system by targeting beta and gamma receptors on cytotoxic T cells. Founded in 2003 and headquartered in La Jolla, California, Ambrx Biopharma Inc. has established significant collaborations with various pharmaceutical partners, including Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health.
Aksjekurs
$28.00
Sist synkronisert: 2024-03-06
Markedsverdi
$1.77B
Endring (1 dag)
0.07%
Endring (1 år)
0.00%
Land
US
Handel Ambrx Biopharma Inc. (AMAM)

Kategori

EPS for Ambrx Biopharma Inc. (AMAM)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Ambrx Biopharma Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Ambrx Biopharma Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH